# SELLAS Life Sciences Group, Inc. Common Stock (SLS)

> SELLAS Life Sciences Group, Inc. Common Stock (SLS) trades at $13.66 (-8.08%) as of 7:59:30 PM EST on Nov 20, 2026, +20.35% over the past month. Market cap is $2.78B, with 6.7 days to cover in short interest.

Canonical: https://massive.com/quote/sls
Data as of: 2026-11-21T00:59:30.135Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$13.66** -1.20 (-8.08%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$14.26** +0.59 (+4.36%)
As of 7:59:30 PM EST on Nov 20, 2026 · After hours

## Stock performance

How SELLAS Life Sciences Group, Inc. Common Stock (SLS) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -8.08% |
| 1W | +73.79% |
| 1M | +20.35% |
| YTD | +262.33% |
| 1Y | +781.29% |
| 52-wk range | $1.39 – $24.89 |

From daily closes through Nov 20, 2026.

## Key statistics

Today's trading snapshot for SLS: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $13.39 – $15.19 |
| Open | $14.98 |
| Prev close | $14.86 |
| Volume | 15.48M |
| Market cap | $2.78B |
| Shares out | 201.95M |

## Valuation and profitability ratios

Valuation and profitability ratios for SELLAS Life Sciences Group, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 22.98 |
| P/FCF | — |
| ROE | -27.1% |
| ROA | -25.4% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 19, 2026

## Insider trading

[SELLAS Life Sciences Group, Inc. Common Stock (SLS) insider trading](https://massive.com/quote/sls/insider-trading.md): open-market Form 4 buys and sells by SELLAS Life Sciences Group, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events SELLAS Life Sciences Group, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 20, 2026 · Underwriting agreement
  “On November 18, 2026, SELLAS Life Sciences Group, Inc. ... entered into an underwriting agreement ... with J.P. Morgan Securities LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein.”
- Nov 17, 2026 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “In the trial, GPS showed a 41% reduction in the risk of death (hazard ratio of 0.59) and a two-sided p=0.035 with a median OS of 24.0 months among GPS-treated patients versus 14.7 months with BAT.”
- Nov 12, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 12, 2026, SELLAS Life Sciences Group, Inc. ("SELLAS") issued a press release (the "Press Release") announcing its financial results for the quarter ended September 30, 2026 and providing a corporate update.”
- Jul 27, 2026 · Material litigation
  “On July 24, 2026, the sole arbitrator in the arbitration proceeding rendered a decision dismissing the Company's claims. As permitted by HKIAC rules, the arbitrator administratively allocated a portion of 3D Medicines' legal fees and costs in the amount of approximately $1.0 million to be paid by the Company.”
- Jun 25, 2026 · Executive compensation change
  “The Stergiou Amendment amends the Stergiou Employment Agreement to provide that certain payments made to Dr. Stergiou as part of his change in control severance benefits will be paid in a lump sum payment.”

## Dividend history and stock splits

SELLAS Life Sciences Group, Inc. Common Stock's recent dividend payments and stock splits.

### Dividends

- $0.24 · ex-div Mar 24, 2011
- $0.42 · ex-div Dec 9, 2010
- $0.15 · ex-div Sep 9, 2010
- $0.09 · ex-div Jun 10, 2010

### Splits

- 1-for-50 · Nov 8, 2019
- 1-for-20 · Nov 14, 2016

## SLS short interest

How heavily SLS is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 6.7 |
| Short interest | 57.13M |
| Avg volume | 8.53M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## SLS news

The latest news and headlines about SELLAS Life Sciences Group, Inc. Common Stock (SLS).

- [SELLAS Life Sciences Announces Pricing of $150.0 Million Underwritten Public Offering](https://www.globenewswire.com/news-release/2026/11/19/3406277/0/en/sellas-life-sciences-announces-pricing-of-150-0-million-underwritten-public-offering.html) · GlobeNewswire Inc. · Nov 18, 2026 · positive sentiment
- [SELLAS anuncia resultados positivos del ensayo pivotal de fase 3 REGAL, que demuestran que la vacuna inmunoterapéutica contra el cáncer galinpepimut-S (GPS) produjo una mejora estadísticamente significativa y clínicamente relevante de la supervivencia global en pacientes con leucemia mieloide aguda](https://www.globenewswire.com/news-release/2026/11/18/3405358/0/es/sellas-anuncia-resultados-positivos-del-ensayo-pivotal-de-fase-3-regal-que-demuestran-que-la-vacuna-inmunoterap%C3%A9utica-contra-el-c%C3%A1ncer-galinpepimut-s-gps-produjo-una-mejora-estad%C3%ADs.html) · GlobeNewswire Inc. · Nov 17, 2026 · positive sentiment
- [SELLAS Life Sciences Divulga Dados Positivos do Estudo REGAL Pivotal de Fase 3, Indicando que Galinpepimut-S (GPS), a Vacina Imunoterapêutica Contra o Câncer, Demonstrou uma Melhora Estatisticamente Significativa e Clinicamente Relevante na Sobrevida Global de Pacientes com Leucemia Mieloide Aguda](https://www.globenewswire.com/news-release/2026/11/18/3405358/0/pt/sellas-life-sciences-divulga-dados-positivos-do-estudo-regal-pivotal-de-fase-3-indicando-que-galinpepimut-s-gps-a-vacina-imunoterap%C3%AAutica-contra-o-c%C3%A2ncer-demonstrou-uma-melhora-est.html) · GlobeNewswire Inc. · Nov 17, 2026 · positive sentiment
- [SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid Leukemia](https://www.globenewswire.com/news-release/2026/11/17/3404429/0/en/sellas-life-sciences-announces-positive-pivotal-phase-3-regal-trial-data-showing-immunotherapeutic-cancer-vaccine-galinpepimut-s-gps-demonstrated-a-statistically-significant-and-cl.html) · GlobeNewswire Inc. · Nov 17, 2026 · positive sentiment
- [INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS](https://www.globenewswire.com/news-release/2026/09/29/3371438/1087/en/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-sellas-life-sciences-group-inc-sls.html) · GlobeNewswire Inc. · Sep 29, 2026 · negative sentiment

## About SELLAS Life Sciences Group, Inc. Common Stock

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 13 |
| Listed | Mar 12, 2008 |

[Company website](https://www.sellaslifesciences.com)

## FAQ

### What is the SELLAS Life Sciences Group, Inc. Common Stock (SLS) stock price today?

SELLAS Life Sciences Group, Inc. Common Stock (SLS) is trading at $13.66 (-8.08% on the day) as of 7:59:30 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is SELLAS Life Sciences Group, Inc. Common Stock?

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications.

### What is the short interest in SLS?

As of Oct 30, 2026, SLS has 57.13M shares short and 6.7 days to cover.

### Does SELLAS Life Sciences Group, Inc. Common Stock (SLS) pay a dividend?

Yes. SELLAS Life Sciences Group, Inc. Common Stock (SLS)'s most recent dividend was $0.24 per share, with an ex-dividend date of Mar 24, 2011. Full SLS dividend history is available from the Massive API.

### What exchange is SLS listed on?

SELLAS Life Sciences Group, Inc. Common Stock (SLS) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time SLS quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=SLS`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [SELLAS Life Sciences Group, Inc. Common Stock (SLS) insider trading](https://massive.com/quote/sls/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
